HALIX opened a 72,000-sf biopharmaceutical development and manufacturing center in November of 2019 at Leiden Bio Science Park in the Netherlands. The five-story structure provides BSL-2 cleanrooms with unidirectional process flows that can easily be upgraded to BSL-3 as needed. A manufacturing line with a 250-liter bioreactor capacity supports the production of viral vaccines and viral vectors, while a separate protein manufacturing area accommodates single-use bioreactors with a capacity of up to 1,000 liters. The facility also houses administrative offices and labs for process development, analytical development, and quality control. Construction began on the project in July of 2018.